In the original publication [1], there was a mistake in Figure 4L as published. Figure 4I and Figure 4L were the same image, displayed with slightly different brightnesses. The corrected Figure 4 appears below.
Figure 4.
BAY-117082 treatment modulated the metastasis process in the lymph node, lung, and spleen. Histological analysis revealed that the treatment with BAY-117082 at doses of 2.5 and 5 mg/kg was able to reduce the degree of metastasis in the lymph node (C,D,M), lung (G,H,N), and spleen (K,L,O) in the C group compared with the OSCC group (B,F,J). (A,E,I) Control groups in the lymph node, lung, and spleen. Data are representative of at least three independent experiments. ND, not designed. *** p < 0.001 vs. sham; ### p < 0.001 and vs. ## p < 0.01 OSCC.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Casili, G.; Scuderi, S.A.; Lanza, M.; Filippone, A.; Mannino, D.; Giuffrida, R.; Colarossi, C.; Mare, M.; Capra, A.P.; De Gaetano, F.; et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).